Protagonist Therapeutics, Inc.
PTGX
$103.88
$3.933.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 132.46% | -133.71% | -18.46% | -13.57% | -105.62% |
| Total Depreciation and Amortization | 70.29% | -261.75% | -27.82% | -2.24% | -70.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.26% | 72.76% | 21.11% | 23.56% | 56.22% |
| Change in Net Operating Assets | -153.78% | 98.41% | 1,168.18% | -101.33% | 151.24% |
| Cash from Operations | -139.04% | -26.72% | 93.05% | -110.71% | 557.05% |
| Capital Expenditure | 60.55% | 53.55% | 88.65% | -2,803.57% | -125.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 197.07% | 681.81% | 71.88% | 163.14% | -1,586.73% |
| Cash from Investing | 196.28% | 659.48% | 71.94% | 162.20% | -1,654.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 96.06% | -29.62% | -53.04% | 13.72% | 52.87% |
| Repurchase of Common Stock | -- | -- | -- | -- | 20.17% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 104.26% | -29.62% | -53.04% | 13.72% | 58.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 54.05% | 143.33% | 75.58% | -84.18% | 399.48% |